La biotecnología en la salud humana: el hito de los anticuerpos monoclonales
DOI:
https://doi.org/10.18002/ambioc.v0i12.4944Palabras clave:
Biología, Ecología. Medio ambiente, Medicina. Salud, Biotecnología roja, Cáncer, Inmunidad, Anticuerpos monoclonales, Inmunización,Resumen
La biotecnología está constituyéndose como una disciplina transversal con interés en diversas áreas como la salud humana y animal, el medioambiente, la agroalimentación, la industria o incluso los recursos marinos. La denominada biotecnología roja es la que se centra en el cuidado de la salud, e intenta mejorar los procedimientos terapéuticos y diagnósticos, implicando para ello al sector farmacéutico, a la investigación biomédica y al conjunto de las tecnologías médicas. En la biotecnología roja el camino ha sido largo, con gran número de fracasos pero también con muchos éxitos; en este artículo de divulgación nos centraremos brevemente en la historia de la biotecnología roja y profundizaremos en uno de sus mayores éxitos: la producción y modificación de anticuerpos monoclonales murinos, quiméricos, humanizados y humanos, con interés en el tratamiento de enfermedades humanas, y se analizarán sus posibles efectos secundarios.
Descargas
Citas
Adams, J.J. y Sidhu, S.S. (2014). Synthetic antibody technologies. Current Opinion in Structural Biology. 24:1-9.
Aksoy, S. et al., (2007). Rituximab-related viral infections in lymphoma patients. Leukemia & Lymphoma. 48:1307-1312.
Alghasham, A. y Rasheed, Z. (2014). Therapeutic targets for rheumatoid arthritis: Progress and promises.Autoimmunity . 47:77-94.
Banerjee, J. (2010). Antibodies are challenged. Indian Journal of Medical Sciences. 64:144-147.
Beck, A. et al., (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nature Reviews. Immunology. 10:345-52.
Biotecnología y Biomedicina. (2013). Informe sectorial. Ayuntamiento de Barcelona, Barcelona, España.
Bowers, P.M. et al., (2013). Mammalian cell display for the discovery and optimization of antibody therapeutics. Methods. 65:44-56.
Brekke, O.H y Sandlie, I. (2003). Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nature Reviews. Drug Discovery 2:52-62.
Brennan, P.J. et al., (2009). Hypersensitivity reactions to mAbs: 105desensitizations in 23 patients, from evaluation to treatment. The Journal of Allergy and Clinical Immunology. 124:1259-66.
Buss, N.A. et al., (2012). Monoclonal antibody therapeutics: history and future. Current opinion in Pharmacology. 12: 615-622.
Campara, M. et al., (2010). Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation. Expert Opinion on Biological Therapy. 10:959-969.
Cao, H. et al., (2013). Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma. Anticancer Research. 33:3879-3885.
Carbajo-Pescador, S. et al., (2013). Inhibition of VEGF expression through blockade of Hif1 and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. British Journal of Cancer. 109:83-91.
Carson, K.R. et al., (2009). Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncology. 10:816-824.
Casanova-Estruch, B. (2013). Safety profile and practical considerations of monoclonal antibody treatment. Neurologia. 28:169-178.
CDC. (2012). Centers for Disease Control and Prevention. Severe acute respiratory syndrome (SARS). http://www.cdc.gov/sars/index.html (acceso: 22/08/2014).
Chen, W. et al., (2012). Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens. Biochemical Biophysical Research Communications. 417:1164-1169.
Chen, W. et al., (2008). Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proceedings of the National Academy of Science of the United States of America. 105:17121-17126.
Ducancel, F. y Muller, B.H. (2014). Molecular engineering of antibodies for therapeutic and diagnostic purposes. Monoclonal Antibodies. 4:445-457.
Elshabrawy, H.A. et al., (2012). Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoSONE. 7:e50366.
EMA. (2013). European Medicines Agency. EU/3/13/1113. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2013/04/human_orphan_001190.jsp&mid=WC0b01ac058001d12 (Acceso: 26/08/214).
Ereky, K. (1919). Biotechnologie der Fleisch-, Fett-, und Milcherzeugung im landwirtschaftlichen Grossbetriebe: für naturwissenschaftlich gebildete Landwirte verfasst. Parey, Berlin, Alemania.
Espiritu, M.J. et al., (2014). A 21st-century approach to age-old problems: the ascension of biologics in clinical therapeutics. Drug Discovery Today. pii: S1359-6446(14)00010-5.
Fowler, N.H. (2011). Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma. P & T: A Peer-reviewed Journal for Formulary Management. 36:590-598.
Fox, J.L. (2006). Turning plants into protein factories. Nature Biotechnology. 24:1191-1193.
Friedrich, B.M. et al., (2012). Potential vaccines and post-exposure treatments for filovirus infections. Viruses. 4:1619-1650.
Genoma España. (2008). Anticuerpos monoclonales terapéuticos. Informe de Vigilancia Tecnológica. Fundación Española para el Desarrollo de la Investigación en Genómica y Proteómica-Fundación General de la Universidad Autónoma de Madrid, Madrid, España.
Giovannoni, G. et al., (2014). Daclizumab high-yield process in relapsingremitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurology. 13:472-481.
Goetsch, C.M. (2011). Genetic tumor profiling and genetically targeted cáncer therapy. Seminars in Oncology Nursing. 27:34-44.
Goodman, J.L. (2014). Studying "secret serums" - Toward safe, effective Ebola treatments. The New England Journal of Medicine. 371:1086-1089.
Hong, D.I. et al., (2012). Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Review of Clinical Immunology. 8:43-52.
Hutfless, S. et al., (2014). Pharmacological management of Crohn's disease: future research needs. Agency for Healthcare Research and Quality, Rockville, Estados Unidos de América.
Kharfan-Dabaja, M.A. (2014). A new dawn for gemtuzumab ozogamicin? Lancet Oncology. 15:913-914.
Kim, S.J. et al., (2005). Antibody engineering for the development of therapeutic antibodies. Molecules and Cells. 20:17-29.
Kirkwood, J.M. et al., (2012). Immunotherapy of cancer in 2012. CA: A Cancer Journal for Clinicians. 62:309-335.
Kitson, S.L. et al., (2013). Radionuclide antibody-conjugates, a targeted therapy towards cancer. Current Radiopharmaceutical. 6:57-71.
Kleyman, K. y Weintraub, D.S. (2012). Monoclonal antibodies: longitudinal prescribing information analysis of hypersensitivity reactions. Monoclonal Antibodies. 4:392-397.
Köhler, G. y Milstein, C. (1975). Continuous cultures of fused cells secreting antobody of predefined specificity. Nature. 256: 495-497.
Kupczyk, M. y Kuna, P. (2014). Omalizumab in an allergology clinic: real life experience and future developments. Postepy Dermatologii Alergologii.31:32-35.
Linke, R. et al., (2010). Catumaxomab: clinical development and future directions. Monoclonal Antibodies. 2:129-136.
Marzi, A., (2012). Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLos ONE.7:e36192.
Mauriz, J.L. y González-Gallego, J. (2008). Antiangiogenic drugs: current knowledge and new approaches to cancer therapy. Journal of Pharmaceutical Science. 97:4129-4154.
Mauriz, J.L. et al., (2003). Antiangiogenic treatment of cáncer. Cirugia Española. 78:3-11.
Michnick, S.W. y Sidhu, S.S. (2008). Submitting antibodies to binding arbitration. Nature Chemical Biology. 4:326-329.
ONT, 2014. Organización Nacional de Trasplantes. http://www.ont.es/home/Paginas/ElModeloEspanol.aspx (acceso: 26/08/2014)
Pasut, G. (2014). Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 28 Suppl 1:15-23.
Pérez-Alvarez, R., (2011). Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 90:359-371.
Pettitt, J. et al., (2013). Therapeutic intervention of Ebola virus infection in Rhesus macaques with the MB-003 monoclonal antibody cocktail. Science Translational Medicine. 5:199(ra)113.
Piaserico, S., (2014). Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Dermato- Venereologica. 94:293-297.
Prabakaran, P. et al., (2012). Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Frontiersin Mocrobiology. 3: 277.
Qiu, X. et al., (2013). Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Scientific Reports. 3:3365.
Rybar, I. et al., (2012). The effectiveness for prevention of tuberculosis in patients with inflammatory rheumatic diseases treated with TNF inhibitors. The International Journal Bratislava Medical Journal – Bratislavske lekarske listy. 109:164-167.
Scheffert, J.L. y Raza, K. (2014). Immunosuppression in lung transplantation. Journal of Thoracic Disease. 6:1039-1053.
Setoguchi, S. et al., (2006). Tumor necrosis factor alpha antagonist use and cáncer in patients with rheumatoid arthritis. Arthritis & Rheumatism. 54:2757-2764.
Shale, M.J. (2009). The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. British Medical Bulletin. 92:61-77.
Sidaway, P. (2014). Transplantation: Alemtuzumab induction reduces acute rejection risk. Nature Reviews Nephrology. En Prensa. doi: 10.1038/nrneph.2014.143.
Smith, J. et al., (2005). Antibody phage display technologies with special reference to angiogenesis. FASEB Journal. 19:331-341.
Smolen, J.S. et al., (2014). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Disease. 73:492-509.
Sorensen, P.S. (2014). New management algorithms in multiple sclerosis. Current Opinion in Neurology. 27:246-259.
Strokappe, N. et al., (2012). Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS ONE. 7:e33298.
Turner, T.L. et al., (2014). Respiratory syncytial virus: current and emerging treatment options. Journal of ClinicoEconomics and Outcomes Research. 6:217-225.
Watanabe, M. et al., (2011). Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection. Luver International. 31:340-347.
Webster, A. et al., (2006). Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane database of Systematic Reviews. 2:CD004756.
WHO. (2014). World Health Organization. Ebola virus disease. http://www.who.int/csr/disease/ebola/en/ (acceso: 21/08/2014).
Williams, C.J. et al., (2014). Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 39:447-458.
Woodworth, C.D. et al., (2005). Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Molecular Cancer Therapeutics. 4:650-665
Zebardast, N. et al., (2010). Rituximab in the management of refractory myasthenia gravis. Muscle & Nerve. 41:375-378.
Zhu, Z. et al., (2013). Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. Virologica Sinica . 28:71-80.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2014 José L. Mauriz, Raquel Ordoñez, Néstor Prieto-Domínguez, Javier González Gallego
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Los autores que publican en esta revista están de acuerdo con los siguientes términos:
- Los autores ceden de forma no exclusiva los derechos de explotación (reproducción, distribución, comunicación pública, transformación) a la Universidad de León, por lo que pueden establecer, por separado, acuerdos adicionales para la distribución no exclusiva de la versión de la obra publicada en la revista (por ejemplo, alojarlo en un repositorio institucional o publicarlo en un libro), con un reconocimiento de su publicación inicial en esta revista.
- Este trabajo se encuentra bajo la Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Puede consultarse desde aquí la versión informativa y el texto legal de la licencia.
- Se permite y se anima a los autores a difundir electrónicamente las versiones pre-print (versión antes de ser evaluada) y/o post-print (versión evaluada y aceptada para su publicación) de sus obras antes de su publicación, ya que favorece su circulación y difusión más temprana y con ello un posible aumento en su citación y alcance entre la comunidad académica.
